Defining survival as an outcome measure in amyotrophic lateral sclerosis

Archives of Neurology

Volumn 66, Issue 6, 2009, Pages 758-761

  Gordon, Paul H ^a,b,g   Corcia, Philippe ^b,c   Lacomblez, Lucette ^b   Pochigaeva, Ksenia ^b   Abitbol, Jean Louis ^d   Cudkowicz, Merit ^e   Leigh, P Nigel ^f   Meininger, Vincent ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

^d Trophos   (France)

^e HARVARD MEDICAL SCHOOL   (United States)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENTOXIFYLLINE; RILUZOLE; XALIPRODEN;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RISK REDUCTION; SURVIVAL RATE; TRACHEOSTOMY; TREATMENT OUTCOME; VITAL CAPACITY;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; HUMANS; KAPLAN-MEIERS ESTIMATE; NAPHTHALENES; OUTCOME ASSESSMENT (HEALTH CARE); PENTOXIFYLLINE; PYRIDINES; RESPIRATION, ARTIFICIAL; RESPIRATORY PARALYSIS; TRACHEOSTOMY; VASODILATOR AGENTS;

EID: 67049145001     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2009.1     Document Type: Article

References (15)

1. World Federation of Neurology Research Group on Neuromuscular Diseases Subcommittee on Motor Neuron Disease; Airlie House "Therapeutic Trials in ALS" Workshop Contributors. Airlie House guidelines: therapeutic trials in amyotrophic lateral sclerosis. J Neurol Sci. 1995;129(suppl):1-10.
2. Bensimon G, Lacomblez L, Meininger V; ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330(9):585-591.
3. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V; Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996;347(9013):1425-1431.
4. Meininger V, Bensimon G, Bradley WR, et al. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(2):107-117. (Pubitemid 39545338)
5. Meininger V, Asselain B, Guillet P, et al; Pentoxifylline European Group. Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial. Neurology. 2006;66(1):88-92.
6. Steiner TJ. Clinical trials. In: Williams AC, ed. Motor Neuron Disease. London, England: Chapman & Hall Medical; 1994:701-724.
7. Gordon PH, Moore DH, Miller RG, et al; Western ALS Study Group. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007;6(12):1045-1053. (Pubitemid 350116691)
8. Maillot F, Laueriere L, Hazouard E, Giraudeau B, Corcia P. Quality of life in ALS is maintained as physical function declines. Neurology. 2001;57(10):1939.
9. De Groot IJ, Post MW, van Heuvein T, Van den Berg LH, Lindeman E. Cross-sectional and longitudinal correlations between disease progression and different health-related quality of life domains in persons with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2007;8(6):356-361. (Pubitemid 350176934)
10. Corcia P, Pradat PF, Salachas F, et al. Causes of death in a post-mortem series of ALS patients. Amyotroph Lateral Scler. 2008;9(1):59-62. (Pubitemid 351260374)
11. Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol. 2006;60(1):22-31.
12. Miller RG, Rosenberg JA, Gelinas DF, et al; ALS Practice Parameters Task Force. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 1999;52(7):1311-1323. (Pubitemid 29190518)
13. Cedarbaum JM, Stambler N; BDNF Study Group. Disease status and use of ventilatory support by ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2(1):19-22. (Pubitemid 32472144)
14. Bourke SC, Gibson GJ. Non-invasive ventilation in ALS: current practice and future role. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(2):67-71. (Pubitemid 39545334)
15. Munsat TL, Andres PL, Finison L, Conlon T, Thibodeaur L. The natural history of motoneuron loss in amyotrophic lateral sclerosis. Neurology. 1988;38(3):409-413. (Pubitemid 18083678)